Cybin Inc. (OTCMKTS:CYBN – Get Free Report)’s share price traded down 5.9% during mid-day trading on Wednesday . The company traded as low as $6.02 and last traded at $6.04. 1,055,340 shares traded hands during trading, an increase of 189% from the average session volume of 365,273 shares. The stock had previously closed at $6.42.
Cybin Stock Performance
The firm has a market cap of $142.48 million, a price-to-earnings ratio of -31.79 and a beta of 0.68. The business’s 50-day moving average is $7.05 and its 200-day moving average is $7.21.
Cybin Company Profile
Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation.
Read More
- Five stocks we like better than Cybin
- What Are Dividend Champions? How to Invest in the Champions
- Cybersecurity Market Set to Double: This ETF Offers Exposure
- Expert Stock Trading Psychology Tips
- Downgraded But Not Done: 3 Stocks Ready for a Market Comeback
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Solana Beat BTC and ETH in Q3: These 3 Stocks Saw It Coming
Receive News & Ratings for Cybin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cybin and related companies with MarketBeat.com's FREE daily email newsletter.
